Allarity Therapeutics (ALLR) AI Stock Analysis

• Market Cap: $18.31M
• Dividend Yield: N/A
• Average Volume (3M): 146.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: 99.82%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 16,057,200
• 10 Day Avg. Volume: 114,973
• 30 Day Avg. Volume: 146,334
• PEG Ratio: <0.01
• Price to Book (P/B): 0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.52
• 1Y Price Target: $9.50
• Price Target Upside: 733.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.91
• Revenue Forecast (FY): $99.78M

• Rating: 42 Neutral
• Price Target: $1.00 ▼(-12.28% Downside)

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and persistent negative free cash flow), partially offset by a currently modestly levered balance sheet with positive equity. Technicals also weigh on the score given the stock trading below major moving averages and a negative MACD, while valuation is limited by negative earnings and no dividend support.

Positive Factors

FDA Fast Track Designation

The FDA Fast Track designation for stenoparib enhances the drug's development and review process, potentially accelerating its market entry and improving Allarity's competitive position in oncology therapeutics.

Clinical Trial Progress

Positive clinical trial results, such as increased median overall survival, strengthen Allarity's drug portfolio and support future commercialization efforts, enhancing long-term growth prospects.

New CFO Appointment

Appointing a full-time CFO demonstrates Allarity's commitment to strengthening financial oversight and strategic planning, which is crucial for managing growth and securing future funding.

Negative Factors

Zero Revenue

Lack of revenue generation limits Allarity's ability to self-fund operations, increasing reliance on external financing and heightening financial risk until product commercialization.

Ongoing Cash Burn

Persistent cash burn reflects operational inefficiencies and necessitates continuous funding, which may dilute shareholder value and constrain long-term financial stability.

Negative Equity Volatility

Historical equity volatility and negative returns highlight financial instability, posing risks to investor confidence and future capital raising efforts.

Allarity Therapeutics Business Overview & Revenue Model

Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Allarity Therapeutics, Inc. generates revenue primarily through strategic partnerships and licensing agreements with other pharmaceutical companies. These collaborations often involve upfront fees, milestone payments, and royalties on future sales of licensed products. The company's revenue model is heavily dependent on advancing its clinical pipeline and securing partnerships for drug development and commercialization. Additionally, Allarity may receive funding through grants and research collaborations aimed at supporting its innovative DRP technology and associated drug development efforts.

Allarity Therapeutics Financial Statement Overview

Summary

Income statement and cash flow are very weak with zero revenue, recurring operating losses, and sustained cash burn (TTM net income -$15.3M; operating cash flow -$14.8M; free cash flow -$15.1M). The balance sheet is a relative bright spot with low debt (~$1.39M) and positive equity (~$12.0M), but historical equity volatility and very negative ROE (~-112%) keep financial risk elevated.

Income Statement

The company reports zero revenue across all periods provided, while continuing to generate sizable operating losses. Profitability is consistently weak: TTM (Trailing-Twelve-Months) net income is -$15.3M and EBIT is -$17.0M, following a larger annual loss in 2024 (net income -$24.5M). A positive note is that losses narrowed from 2024 to TTM (Trailing-Twelve-Months), suggesting some cost containment, but the absence of revenue keeps the earnings profile high-risk and heavily dependent on future commercialization or funding.

Balance Sheet

Leverage appears modest in absolute terms (TTM total debt ~$1.39M), and equity is positive in the most recent periods (TTM equity ~$12.0M; 2024 equity ~$11.8M), which supports near-term balance sheet stability. However, the track record shows meaningful volatility—equity was negative in 2023 (-$2.8M), highlighting dilution/financing and accumulated-loss risk typical of early-stage biotech. Returns to shareholders are clearly unfavorable (TTM return on equity around -112%), reflecting ongoing losses despite the currently positive equity base.

Cash Flow

Cash generation remains a key weakness, with persistent cash burn: TTM (Trailing-Twelve-Months) operating cash flow is -$14.8M and free cash flow is -$15.1M, after even heavier cash outflows in 2024 (operating cash flow -$17.4M; free cash flow -$17.7M). While cash burn improved versus 2024, TTM free cash flow growth is still negative (-11.9%), and cash flows remain firmly negative overall. Free cash flow is roughly in line with reported losses (TTM free cash flow to net income ~1.02), indicating the losses are translating into real cash usage rather than being primarily non-cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-15.09M	-24.23M	-11.28M	-17.30M	-25.77M	-6.01M
Net Income	-15.31M	-24.52M	-11.90M	-16.06M	-26.65M	-6.60M
Balance Sheet
Total Assets	20.80M	22.65M	11.86M	14.54M	49.63M	33.40M
Cash, Cash Equivalents and Short-Term Investments	16.89M	19.53M	166.00K	2.03M	19.91M	298.00K
Total Debt	1.39M	1.35M	1.30M	3.73M	1.09M	2.67M
Total Liabilities	8.79M	10.84M	14.61M	12.65M	30.85M	8.96M
Stockholders Equity	12.01M	11.81M	-2.75M	1.89M	18.78M	24.44M
Cash Flow
Free Cash Flow	-15.08M	-17.65M	-12.74M	-16.84M	-15.05M	-7.25M
Operating Cash Flow	-14.78M	-17.35M	-12.74M	-16.82M	-15.05M	-7.25M
Investing Cash Flow	-298.00K	-298.00K	0.00	791.00K	1.00M	-3.00K
Financing Cash Flow	15.12M	36.79M	10.99M	-1.31M	33.82M	6.03M

Allarity Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.14
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Positive. The current price of 1.14 is above the 20-day moving average (MA) of 1.09, below the 50-day MA of 1.15, and below the 200-day MA of 1.16, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.80 is Neutral, neither overbought nor oversold. The STOCH value of 80.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLR.

Allarity Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LSTA	48 Neutral	$18.35M	-1.00	-71.45%	―	―	15.32%
CRIS	45 Neutral	$11.83M	-0.24	―	―	13.56%	52.92%
ALLR	42 Neutral	$18.31M	-0.75	-122.61%	―	―	99.82%
LGVN	40 Underperform	$12.20M	-0.41	-119.92%	―	-22.41%	78.88%

Allarity Therapeutics Corporate Events

Allarity Therapeutics Completes Additional Private Equity Financing

On September 22, 2025, Allarity Therapeutics entered into a securities purchase agreement with an accredited investor for a private placement of 1,562,500 shares of common stock and/or pre-funded warrants, raising approximately $2.5 million in gross proceeds, and on December 23, 2025, the company completed an additional closing under that agreement. At this additional closing, Allarity sold a further 255,103 common shares at $0.98 per share, the minimum price permitted under Nasdaq rules, generating about $250,000 in gross proceeds that it plans to use for general corporate purposes and working capital, with the unregistered securities issued under a private placement exemption and subject to restrictive legends, highlighting the company’s continued reliance on exempt equity financings to support its operations.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.

Allarity Therapeutics Appoints Jeffrey Ervin as Full-Time CFO

On December 3, 2025, Allarity Therapeutics, Inc. transitioned Jeffrey S. Ervin from a part-time to a full-time Chief Financial Officer role under a new employment agreement. This agreement includes an annual base salary of $367,700, restricted stock units, and a performance bonus, reflecting the company’s commitment to strengthening its financial leadership.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.